Untargeted Metabolomics Showed Accumulation of One-Carbon Metabolites to Facilitate DNA Methylation during Extracellular Matrix Detachment of Cancer Cells.
DNA methylation
ECM detachment
NKG2DLs
anoikis
one-carbon metabolism
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
21 Mar 2022
21 Mar 2022
Historique:
received:
22
02
2022
revised:
15
03
2022
accepted:
16
03
2022
entrez:
24
3
2022
pubmed:
25
3
2022
medline:
25
3
2022
Statut:
epublish
Résumé
Tumor cells detached from the extracellular matrix (ECM) undergo anoikis resistance and metabolic reprogramming to facilitate cancer cell survival and promote metastasis. During ECM detachment, cancer cells utilize genomic methylation to regulate transcriptional events. One-carbon (1C) metabolism is a well-known contributor of SAM, a global substrate for methylation reactions, especially DNA methylation. DNA methylation-mediated repression of NK cell ligands MICA and MICB during ECM detachment has been overlooked. In the current work, we quantitated the impact of ECM detachment on one-carbon metabolites, expression of 1C regulatory pathway genes, and total methylation levels. Our results showed that ECM detachment promotes the accumulation of one-carbon metabolites and induces regulatory pathway genes and total DNA methylation. Furthermore, we measured the expression of well-known targets of DNA methylation in NK cell ligands in cancer cells, namely, MICA/B, during ECM detachment and observed low expression compared to ECM-attached cancer cells. Finally, we treated the ECM-detached cancer cells with vitamin C (a global methylation inhibitor) and observed a reduction in the promoter methylation of NK cell ligands, resulting in MICA/B re-expression. Treatment with vitamin C was also found to reduce global DNA methylation levels in ECM-detached cancer cells.
Identifiants
pubmed: 35323710
pii: metabo12030267
doi: 10.3390/metabo12030267
pmc: PMC8951017
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : King Abdulaziz University
ID : KEP-15-130-38
Références
Trends Cancer. 2016 Jun;2(6):295-304
pubmed: 28741527
Leukemia. 2007 Oct;21(10):2103-8
pubmed: 17625602
Trends Cancer. 2017 Jul;3(7):475-481
pubmed: 28718402
Science. 2001 Aug 10;293(5532):1089-93
pubmed: 11498579
Cell Death Dis. 2014 Nov 20;5:e1525
pubmed: 25412303
J Hepatol. 2000 Dec;33(6):907-14
pubmed: 11131452
Redox Biol. 2020 Sep;36:101643
pubmed: 32863227
Biochim Biophys Acta. 2013 Dec;1833(12):3481-3498
pubmed: 23830918
Oncogenesis. 2016 Jan 25;5:e190
pubmed: 26807645
BMC Cancer. 2014 Mar 17;14:196
pubmed: 24636201
Cancer Lett. 2020 Oct 1;489:19-28
pubmed: 32512023
Int J Mol Sci. 2019 Apr 19;20(8):
pubmed: 31010154
Cancer Lett. 2020 Feb 1;470:141-148
pubmed: 31759958
J Genet Genomics. 2009 Apr;36(4):203-14
pubmed: 19376481
Trends Cell Biol. 2018 Sep;28(9):698-708
pubmed: 29724526
Nat Rev Cancer. 2014 Sep;14(9):632-41
pubmed: 25098270
Nutrients. 2020 Jun 17;12(6):
pubmed: 32560283
Sci Rep. 2019 Dec 3;9(1):18236
pubmed: 31796828
Genes Immun. 2015 Jan-Feb;16(1):71-82
pubmed: 25393931
Nature. 2016 Sep 1;537(7618):63-68
pubmed: 27533040
Immunity. 2008 Apr;28(4):571-80
pubmed: 18394936
Front Immunol. 2017 Sep 13;8:1124
pubmed: 28955340
Cell Death Differ. 2016 Aug;23(8):1271-82
pubmed: 26915296
Cell Metab. 2019 Oct 1;30(4):720-734.e5
pubmed: 31447323
Front Oncol. 2014 Aug 25;4:227
pubmed: 25202679
Cancer Res. 1998 Apr 1;58(7):1444-50
pubmed: 9537246
Nat Rev Mol Cell Biol. 2019 Oct;20(10):590-607
pubmed: 31399642
Br J Cancer. 2017 Apr 25;116(9):1208-1217
pubmed: 28334733
Immunity. 2002 Jul;17(1):19-29
pubmed: 12150888
Front Pharmacol. 2018 Oct 18;9:1173
pubmed: 30405408
Epigenetics. 2015;10(1):82-91
pubmed: 25531272
J Genet Genomics. 2009 May;36(5):277-82
pubmed: 19447375
Curr Immunol Rev. 2009 Feb;5(1):22-34
pubmed: 19626129
Front Immunol. 2017 Jan 19;7:687
pubmed: 28154561
Front Oncol. 2021 Feb 25;11:612778
pubmed: 33718166
Stem Cells Int. 2019 Mar 10;2019:3894101
pubmed: 30956668
Clin Epigenetics. 2015 Sep 11;7:98
pubmed: 26366235
Annu Rev Immunol. 2013;31:413-41
pubmed: 23298206
Oncogene. 2008 Oct 6;27(45):5944-58
pubmed: 18836475
Mol Cell Proteomics. 2010 Dec;9(12):2617-28
pubmed: 20699381
Annu Rev Nutr. 2015;35:545-64
pubmed: 25974700
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
BMC Cancer. 2013 Aug 02;13:369
pubmed: 23915286
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3509-E3518
pubmed: 29581297
Front Cell Dev Biol. 2019 Jul 16;7:128
pubmed: 31380368
Br J Cancer. 2017 Jun 6;116(12):1499-1504
pubmed: 28472819
Nat Rev Genet. 2018 Feb;19(2):81-92
pubmed: 29033456
Nat Rev Genet. 2013 Mar;14(3):204-20
pubmed: 23400093
Trends Cell Biol. 2018 Aug;28(8):673-684
pubmed: 29747903
Int J Cancer. 2009 Oct 1;125(7):1626-39
pubmed: 19569244
Sci Rep. 2016 Feb 23;6:21678
pubmed: 26902929
Front Immunol. 2018 Mar 12;9:476
pubmed: 29662484
Mol Cell Biol. 2008 Jan;28(2):752-71
pubmed: 17991895
Epigenetics. 2015;10(8):671-6
pubmed: 26098813
J Neurochem. 2021 Jun;157(6):1759-1773
pubmed: 32219848
Oncol Lett. 2019 Sep;18(3):3115-3127
pubmed: 31452789
Neurotherapeutics. 2018 Jan;15(1):156-175
pubmed: 29340929
Nutrients. 2019 Mar 13;11(3):
pubmed: 30871166
Br J Cancer. 2008 May 6;98(9):1555-61
pubmed: 18414409
Nat Rev Cancer. 2014 Jun;14(6):430-9
pubmed: 24827502
Mol Cell. 2019 Sep 19;75(6):1147-1160.e5
pubmed: 31420217
J Biol Chem. 2014 Nov 21;289(47):32639-55
pubmed: 25271158